This review highlights the potential of targeting epigenetic markers in early interventions, suggesting new avenues for preventing schizophrenia.
Schizophrenia is a neurological disorder that affects an individual’s perception of themselves and the world around them. In recent years, research on schizophrenia has plateaued, with much of the focus placed on post-onset treatments, such as the use of antipsychotic medications and psychotherapy. Although the disorder has been extensively studied, the prodromal stage—preceding the onset of psychosis—remains relatively underexplored. We assert in this scientific review that the prodromal stage offers significant promise in the prevention or strong reduction of schizophrenic symptoms and has been overlooked by previous research. Emerging studies suggest that both pharmacological and psychological interventions targeting epigenetic markers may offer promising new approaches for early-stage treatment.
No takes yet. Share an insight, caveat, or question.
Fischer-Zimmermann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: